title: Equivalence of ceftriaxone and rifampicin in eliminating nasopharyngeal carriage of serogroup B Neisseria meningitidis.
abstract: The efficacy of ceftriaxone in eliminating nasopharyngeal carriage of Neisseria meningitidis was compared with that of rifampicin during an epidemic of serogroup B meningococcal disease in Auckland, New Zealand. Household contacts of cases had a throat swab taken and were randomized to treatment. Carriers had a repeat swab taken 6 days later to determine efficacy of treatment. Ceftriaxone (98.2%) was equivalent to rifampicin (97.6%) in eliminating serogroup B N. meningitidis. It is cheaper than rifampicin and has the advantage of full compliance and fewer contraindications, but its acceptability by patients may limit its use as a first-line prophylactic agent.
authors.affiliation: Auckland Healthcare Public Health Protection, Auckland, New Zealand. gregs@ahsl.co.nz
authors.forename: G
authors.initials: G
authors.lastname: Simmons
authors.forename: N
authors.initials: N
authors.lastname: Jones
authors.forename: L
authors.initials: L
authors.lastname: Calder
mesh_terms: D000293:Adolescent; D000328:Adult; D000904:Antibiotics, Antitubercular / Q000009:adverse effects / Q000627:therapeutic use*; D002353:Carrier State / Q000188:drug therapy* / Q000382:microbiology; D002443:Ceftriaxone / Q000009:adverse effects / Q000627:therapeutic use*; D002511:Cephalosporins / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008589:Meningococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D009305:Nasopharynx / Q000382:microbiology; D009345:Neisseria meningitidis; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use*; D012703:Serotyping
chemical_list: D000904:Antibiotics, Antitubercular; D002511:Cephalosporins; D002443:Ceftriaxone; D012293:Rifampin